Adalimumab Antibodies / Anti Drug Antibodies (ADA)

Immunology

---

Description

Adalimumab is a monoclonal antibody directed towards TNF alpha [1]. It is used in the treatment of chronic inflammatory conditions such as inflammatory bowel disease and rheumatic disease [1,2,3]. Ongoing use of Adalimumab may initiate an immune response in a subgroup of patients leading to the production of anti-adalimumab antibodies. These antibodies neutralise the effect of the drug. Patients with positive anti-adalimumab antibodies are more likely to have infusion related reactions and loss of response to the therapy over time [2,4]. The measurement of Adalimumab drug levels and Adalimumab antibody levels can aid in clinical decision making by identifying if a trough therapeutic drug level has been reached and determining if anti-drug antibodies are present if the trough level is low. Dose may be increased if there are no anti-drug antibodies present, or stopped if the patient has developed antibodies [2].

---

Indications

Investigation of low trough Adalimumab level or in patients experiencing adverse reactions following Adalimumab infusion.

---

Sample Type

Serum (Gel 5ml Yellow) or Plasma (2mL EDTA).
Requests from outside Sheffield: transport at ambient temperature via Royal Mail or Courier.

---

Reference Range

Negative = <10 AU/mL

---

Turnaround Time

Within 10 days

---

Testing Frequency

As required

---

References

Tracey D, et al. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacology and Therapeutics. 2008. 117: 244-279. [Ref 1].
Mayzor Y, et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. Alimentary Pharmacology and Therapeutics. 2014. 40:620-628. [Ref 2].
Bradley JR. TNF-mediated inflammatory disease. J Pathol 214: 149-160. [Ref 3].
Bender NK, et al. Immunogenicity, efficacy and adverse effects of adalimumab in RA patients. Rheumatol Int. 27: 269-274. [Ref 4].

---

See Also

Adalimumab drug level

Please note: the above information is subject to change and we endeavour to keep this website up to date wherever necessary.